Zoledronic Acid (ZometaR) On Top Of Endocrine Therapy Boosts Survival In Premenopaus

[News]

The addition of zoledronic acid (ZometaR) to adjuvant endocrine therapy in premenopausal women with early breast cancer significantly reduces the risk of disease-free and recurrence-free survival events by about a third, according to results released at the 33rd Annual Congress of the European Society of Medical Oncology (ESMO.

More... (http://www.medicalnewstoday.com/articles/121669.php)